Shahin Keshtkar Rajabi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shahin Keshtkar Rajabi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Amin Abbasi
Firoozabadi hospital clinical research development unit (FHCRDU), Department of internal medicine, school of medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
6 shared publications - Amir Ziaee
Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
2 shared publications - Ehsan Rikhtegar
Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2 shared publications - Farshad Divsalar
Firoozgar General Hospital, Department of Infectious Disease, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
2 shared publications - Mohammad Amin Abbasi
Firoozabadi Clinical Research Development Unit, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publications - Nima Azh
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 11 (2) , 186-192
De novo ECG changes in patients without a history of heart problems presenting with acute cholecystitis: etiology and clinical importance
Background & Aims: Acute cholecystitis, primarily an inflammatory condition of the gallbladder, has been associated with electrocardiographic (ECG) changes that mimic cardiac pathology. While laparoscopic cholecystectomy is a well-established treatment for acute cholecystitis, its potential impact on postoperative ECG changes in patients without pre-existing cardiovascular disease remains unclear. This study aims ...
- 1 April 2025
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 11 (2) , 186-192
Open AccessDe novo ECG changes in patients without a history of heart problems presenting with acute cholecystitis: etiology and clinical importance
Background & Aims: Acute cholecystitis, primarily an inflammatory condition of the gallbladder, has been associated with electrocardiographic (ECG) changes that mimic cardiac pathology. While laparoscopic cholecystectomy is a well-established treatment for acute cholecystitis, its potential impact on postoperative ECG changes in patients without pre-existing cardiovascular disease remains unclear. This study aims ...
- Open Access
- 1 January 2025
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 11 (1) , 11-18
The CD4 cell level as a predictive factor for the outcome severity and prognosis of patients with COVID-19
Background & Aims: Coronavirus disease 2019 (COVID-19) leads to the activation of immune cells, especially in patients developing severe disease, and induces lymphopenia, primarily affecting the cluster of differentiation 4 T-cell (CD4+ T) subset. The presence of lymphopenia and cytokine storm may play a major role in the pathogenesis of COVID-19. This ...
- 1 January 2025
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 11 (1) , 11-18
Open AccessThe CD4 cell level as a predictive factor for the outcome severity and prognosis of patients with COVID-19
Background & Aims: Coronavirus disease 2019 (COVID-19) leads to the activation of immune cells, especially in patients developing severe disease, and induces lymphopenia, primarily affecting the cluster of differentiation 4 T-cell (CD4+ T) subset. The presence of lymphopenia and cytokine storm may play a major role in the pathogenesis of COVID-19. This ...
- Open Access
- 1 November 2024
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 10 (4) , 310-317
Clinical consequences of tocilizumab consumption time on COVID-19 patients
Background & Aims: Studies have shown that treating COVID-19 with tocilizumab is associated with lower death risks and mechanical ventilation needs. However, the definite effectiveness of this drug based on the timing of its use is still controversial due to various findings. Some studies have shown that the timing of ...
- 1 November 2024
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 10 (4) , 310-317
Open AccessClinical consequences of tocilizumab consumption time on COVID-19 patients
Background & Aims: Studies have shown that treating COVID-19 with tocilizumab is associated with lower death risks and mechanical ventilation needs. However, the definite effectiveness of this drug based on the timing of its use is still controversial due to various findings. Some studies have shown that the timing of ...
- Open Access
- 28 October 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (2)
Investigating the Relationship Between Demographic and Laboratory Factors with the Incidence of PTE in COVID-19
Background: In 2019, after the first case was discovered in Wuhan, China, the COVID-19 virus began to spread rapidly across the world, leading the WHO to declare the disease a public health emergency. Objectives: Thromboembolism refers to the formation of a clot in a vein, which then travels through the vascular system, potentially blocking blood flow in another location. Methods: This retrospective cohort study aimed to investigate the risk factors for pulmonary embolism in COVID-19 patients hospitalized at Firoozabadi Hospital from May to the end of December 2020. After extracting the required information, the data was entered into SPSS version 26 software for analysis. Results: In total, data from 283 COVID-19 patients admitted to Firouzabadi Hospital in Tehran in 2020 were collected. The average age of the patients was 58.8 ± 15.9 years. Among the 283 patients, 162 (57.6%) were male, 79 patients (27.9%) had pulmonary embolism, 102 patients (36%) were smokers, and 107 patients (37.8%) had a history of hypertension. A significant relationship was observed between the occurrence of pulmonary embolism and elevated levels of, white blood cells (WBC) (P = 0.0001), lactate dehydrogenase (LDH) (P = 0.0001), D-dimer (P = 0.0001), polymorphonuclear neutrophils (PMN) (P = 0.020), lymphocytes (P = 0.013), alkaline phosphatase (Alk.P) (P = 0.025), alanine aminotransferase (ALT) (P = 0.019), and aspartate aminotransferase (AST) (P = 0.017). Conclusions: Based on the results of this study, the incidence of pulmonary embolism in hospitalized COVID-19 patients who underwent CT angiography due to clinical suspicion of thrombosis was 27.9%. Additionally, factors such as smoking, a previous history of pulmonary thromboembolism, high WBC, elevated liver function tests (LFT), and elevated LDH levels were identified as risk factors for the occurrence of pulmonary embolism in these patients.
- 28 October 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (2)
Open AccessInvestigating the Relationship Between Demographic and Laboratory Factors with the Incidence of PTE in COVID-19
Background: In 2019, after the first case was discovered in Wuhan, China, the COVID-19 virus began to spread rapidly across the world, leading the WHO to declare the disease a public health emergency. Objectives: Thromboembolism refers to the formation of a clot in a vein, which then travels through the vascular system, potentially blocking blood flow in another location. Methods: This retrospective cohort study aimed to investigate the risk factors for pulmonary embolism in COVID-19 patients hospitalized at Firoozabadi Hospital from May to the end of December 2020. After extracting the required information, the data was entered into SPSS version 26 software for analysis. Results: In total, data from 283 COVID-19 patients admitted to Firouzabadi Hospital in Tehran in 2020 were collected. The average age of the patients was 58.8 ± 15.9 years. Among the 283 patients, 162 (57.6%) were male, 79 patients (27.9%) had pulmonary embolism, 102 patients (36%) were smokers, and 107 patients (37.8%) had a history of hypertension. A significant relationship was observed between the occurrence of pulmonary embolism and elevated levels of, white blood cells (WBC) (P = 0.0001), lactate dehydrogenase (LDH) (P = 0.0001), D-dimer (P = 0.0001), polymorphonuclear neutrophils (PMN) (P = 0.020), lymphocytes (P = 0.013), alkaline phosphatase (Alk.P) (P = 0.025), alanine aminotransferase (ALT) (P = 0.019), and aspartate aminotransferase (AST) (P = 0.017). Conclusions: Based on the results of this study, the incidence of pulmonary embolism in hospitalized COVID-19 patients who underwent CT angiography due to clinical suspicion of thrombosis was 27.9%. Additionally, factors such as smoking, a previous history of pulmonary thromboembolism, high WBC, elevated liver function tests (LFT), and elevated LDH levels were identified as risk factors for the occurrence of pulmonary embolism in these patients.
- Open Access
- 2 June 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (1)
Prevalence and Risk Factors of Cardiac Arrhythmia in COVID-19 Patients
Background: Previous studies have shown that cardiac arrhythmias may occur in up to 44% of patients with severe COVID-19. Objectives: This study aims to evaluate the incidence of cardiac arrhythmias in patients with COVID-19 and their risk factors. Methods: In this retrospective observational study, we included 288 consecutive COVID-19 patients who were admitted to the emergency department. Patients with a history of old arrhythmia, including atrial fibrillation, flutter, and atrial tachycardia, were excluded. Electrocardiographic data were collected in the first 24 hours of hospitalization, and hematological biomarkers were measured. Results: Arrhythmia occurred in 23.6% of patients and 61.8% of ICU patients. Its prevalence was significantly higher in ICU patients compared to ward patients. Arrhythmias were categorized as atrial fibrillation (11.8%), ventricular tachycardia (4.2%), premature ventricular contraction (2.7%), and paroxysmal supraventricular tachycardia (2.4%). Gender, age, and lab tests were not associated with the incidence of arrhythmia in COVID-19 patients. Conclusions: Arrhythmia was observed in 23.6% of patients with COVID-19 and in 61.8% of ICU patients with COVID-19. No risk factor was found for cardiac arrhythmia in COVID-19 patients.
- 2 June 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (1)
Open AccessPrevalence and Risk Factors of Cardiac Arrhythmia in COVID-19 Patients
Background: Previous studies have shown that cardiac arrhythmias may occur in up to 44% of patients with severe COVID-19. Objectives: This study aims to evaluate the incidence of cardiac arrhythmias in patients with COVID-19 and their risk factors. Methods: In this retrospective observational study, we included 288 consecutive COVID-19 patients who were admitted to the emergency department. Patients with a history of old arrhythmia, including atrial fibrillation, flutter, and atrial tachycardia, were excluded. Electrocardiographic data were collected in the first 24 hours of hospitalization, and hematological biomarkers were measured. Results: Arrhythmia occurred in 23.6% of patients and 61.8% of ICU patients. Its prevalence was significantly higher in ICU patients compared to ward patients. Arrhythmias were categorized as atrial fibrillation (11.8%), ventricular tachycardia (4.2%), premature ventricular contraction (2.7%), and paroxysmal supraventricular tachycardia (2.4%). Gender, age, and lab tests were not associated with the incidence of arrhythmia in COVID-19 patients. Conclusions: Arrhythmia was observed in 23.6% of patients with COVID-19 and in 61.8% of ICU patients with COVID-19. No risk factor was found for cardiac arrhythmia in COVID-19 patients.
- Open Access
- 8 March 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (7) , 914-921
Post‐load glucose is a stronger predictor of adverse pregnancy outcomes than first‐trimester HbA1c in women without gestational diabetes
Aims/Introduction: A debate exists on the relation of adverse pregnancy outcomes with glycemic levels in early pregnancy. We aimed to investigate the association of maternal characteristics including post‐load glucose and first‐trimester HbA1c test results with adverse pregnancy outcomes in women without gestational diabetes mellitus.Materials and Methods: A dataset (January 2011 and September 2017) from a hospital prenatal clinic was explored to find the important predictors of adverse pregnancy outcomes using maternal characteristics and glucose assessments in mothers without gestational diabetes. We used two machine learning algorithms to capture nonlinearity in selecting important maternal characteristics and developed predictive models for each outcome. In total, 1,618 pregnant women were included in the analytic dataset with a mean (SD) age of 26.8 (3.5) years and gravida of 1.7 (0.9).Results: Important associations were detected between maternal features and primary cesarean section, fetal distress, premature rupture of membranes, macrosomia, small or large for gestational age, APGAR <7 at 1 or 5 min, hyperbilirubinemia, and poly‐ or oligo‐hydramnios. Overall, the predictive models showed good performance and large areas under the curves (0.732, 0.765, 0.646, 0.651, 0.730, 0.646, 0.684, 0.716, and 0.678, respectively). Specifically, they had high positive likelihood ratios.Conclusions: High glucose levels were associated with adverse pregnancy outcomes. Post‐load glucose was the most reliable test for predicting the outcomes. Overall, fasting blood sugar was of more predictive value than HbA1c. Our study showed that further research should account for the nonlinearity and interactions inherent in the data.
- 8 March 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (7) , 914-921
Open AccessPost‐load glucose is a stronger predictor of adverse pregnancy outcomes than first‐trimester HbA1c in women without gestational diabetes
Aims/Introduction: A debate exists on the relation of adverse pregnancy outcomes with glycemic levels in early pregnancy. We aimed to investigate the association of maternal characteristics including post‐load glucose and first‐trimester HbA1c test results with adverse pregnancy outcomes in women without gestational diabetes mellitus.Materials and Methods: A dataset (January 2011 and September 2017) from a hospital prenatal clinic was explored to find the important predictors of adverse pregnancy outcomes using maternal characteristics and glucose assessments in mothers without gestational diabetes. We used two machine learning algorithms to capture nonlinearity in selecting important maternal characteristics and developed predictive models for each outcome. In total, 1,618 pregnant women were included in the analytic dataset with a mean (SD) age of 26.8 (3.5) years and gravida of 1.7 (0.9).Results: Important associations were detected between maternal features and primary cesarean section, fetal distress, premature rupture of membranes, macrosomia, small or large for gestational age, APGAR <7 at 1 or 5 min, hyperbilirubinemia, and poly‐ or oligo‐hydramnios. Overall, the predictive models showed good performance and large areas under the curves (0.732, 0.765, 0.646, 0.651, 0.730, 0.646, 0.684, 0.716, and 0.678, respectively). Specifically, they had high positive likelihood ratios.Conclusions: High glucose levels were associated with adverse pregnancy outcomes. Post‐load glucose was the most reliable test for predicting the outcomes. Overall, fasting blood sugar was of more predictive value than HbA1c. Our study showed that further research should account for the nonlinearity and interactions inherent in the data.
- Open Access
- 1 October 2023
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 9 (4) , 229-232
A Patient with Brucella with initial Manifestations similar to Crimean Congo Fever
The unusual manifestations of brucellosis as an endemic disease involving multiple organ systems include headache, confusion, acute abdomen, psoas abscess, endocarditis, perinephric mass, insulin resistance, and cauda-equina syndrome. In this paper we report a patient with such situations that was initially diagnosed and treated for Crimean-Congo hemorrhagic fever (CCHF) with partial ...
- 1 October 2023
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 9 (4) , 229-232
Open AccessA Patient with Brucella with initial Manifestations similar to Crimean Congo Fever
The unusual manifestations of brucellosis as an endemic disease involving multiple organ systems include headache, confusion, acute abdomen, psoas abscess, endocarditis, perinephric mass, insulin resistance, and cauda-equina syndrome. In this paper we report a patient with such situations that was initially diagnosed and treated for Crimean-Congo hemorrhagic fever (CCHF) with partial ...
- Open Access
- 1 July 2023
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 9 (3) , 138-142
An Interesting Case with Extrapulmonary Manifestations of Sarcoidosis
Sarcoidosis is characterized by a various courses and clinical presentation and in this era, some patients may have some symptoms difficult to establish the sarcoidosis diagnosis. Here we report a new case of sarcoidosis with some learning points for the clinicians. We report a 39-year-old male patient attending to the clinic due to ...
- 1 July 2023
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 9 (3) , 138-142
Open AccessAn Interesting Case with Extrapulmonary Manifestations of Sarcoidosis
Sarcoidosis is characterized by a various courses and clinical presentation and in this era, some patients may have some symptoms difficult to establish the sarcoidosis diagnosis. Here we report a new case of sarcoidosis with some learning points for the clinicians. We report a 39-year-old male patient attending to the clinic due to ...
- Open Access
- 27 December 2022
- Published by SCI AND TECH UNIVERSAL INC in Journal of Obstetrics, Gynecology and Cancer Research
- Vol. 8 (1) , 29-34
Evaluation of Prolactin Receptor in Triple Negative Breast Cancer by Immunohistochemistry as a Predictive Factor: A Descriptive Analytic Study
Background & Objective: There are controversial results and paucity of data regarding the role of prolactin hormone in triple negative breast cancer. Hence, this study aimed to evaluate the role of prolactin receptor as a predictive factor in patients with triple negative breast cancer.Materials & Methods: This was a descriptive-analytical study. All patients referred to three referral hospitals with triple negative breast cancer (ER−, PR−, HER-2−), were assessed to be included in the study. Patients' slides and blocks were re-examined for prolactin receptor by immunohistochemistry. Moreover, the association between the tumor size and grade was examined with prolactin receptor. Clinical characteristics and pathological features were recorded in researcher made questionnaire.Results: In total, 25 patients with triple negative breast cancer (TNBC) entered the study. Mean and standard deviation (SD) of tumor size in prolactin negative and positive groups were 4.82 ± 5.05 and 3.37 ± 1.61 cm, respectively with no significant difference (P-value> 0.05). Also, there was no statistically significant association between the tumor grade and prolactin receptor status (P-value = 0.056). Moreover, there was no statistically significant association between lymph nodes involvement and prolactin receptor status using Fisher’s exact test (P-value = 0.9). However, mean ± SD of age in negative and positive prolactin groups were 45.73 ± 12.12 and 56.60 ± 9.84, respectively with a statistically significant difference (P-value = 0.026).Conclusion: We did not find any association between prolactin receptor status and tumor size or grade in TNBC. Nonetheless, there is still ambiguity regarding the role of prolactin receptor expression in development of breast cancer. The controversial results are probably due to different effects of prolactin receptor in various breast cancer subtypes, which should be assessed in further trials.
- 27 December 2022
- Published by SCI AND TECH UNIVERSAL INC in Journal of Obstetrics, Gynecology and Cancer Research
- Vol. 8 (1) , 29-34
Open AccessEvaluation of Prolactin Receptor in Triple Negative Breast Cancer by Immunohistochemistry as a Predictive Factor: A Descriptive Analytic Study
Background & Objective: There are controversial results and paucity of data regarding the role of prolactin hormone in triple negative breast cancer. Hence, this study aimed to evaluate the role of prolactin receptor as a predictive factor in patients with triple negative breast cancer.Materials & Methods: This was a descriptive-analytical study. All patients referred to three referral hospitals with triple negative breast cancer (ER−, PR−, HER-2−), were assessed to be included in the study. Patients' slides and blocks were re-examined for prolactin receptor by immunohistochemistry. Moreover, the association between the tumor size and grade was examined with prolactin receptor. Clinical characteristics and pathological features were recorded in researcher made questionnaire.Results: In total, 25 patients with triple negative breast cancer (TNBC) entered the study. Mean and standard deviation (SD) of tumor size in prolactin negative and positive groups were 4.82 ± 5.05 and 3.37 ± 1.61 cm, respectively with no significant difference (P-value> 0.05). Also, there was no statistically significant association between the tumor grade and prolactin receptor status (P-value = 0.056). Moreover, there was no statistically significant association between lymph nodes involvement and prolactin receptor status using Fisher’s exact test (P-value = 0.9). However, mean ± SD of age in negative and positive prolactin groups were 45.73 ± 12.12 and 56.60 ± 9.84, respectively with a statistically significant difference (P-value = 0.026).Conclusion: We did not find any association between prolactin receptor status and tumor size or grade in TNBC. Nonetheless, there is still ambiguity regarding the role of prolactin receptor expression in development of breast cancer. The controversial results are probably due to different effects of prolactin receptor in various breast cancer subtypes, which should be assessed in further trials.
- Open Access
- 11 September 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (2)
Efficacy of Dexamethasone and Methylprednisolone in Hospitalization Outcomes of COVID-19 Patients: A Comparative Retrospective Study
Background: Control of the COVID-19 pandemic, its treatment, and prevention of mortality and morbidity have been the main focus of researchers over the past two years. Due to disagreement on the usefulness of different corticosteroids in the treatment of COVID-19, this work compared the efficacy of dexamethasone and methylprednisolone in the treatment outcomes of intensive critical care (ICU) patients. Methods: The present retrospective cohort study examined clinical records of 105 COVID-19 patients hospitalized in the ICUs of Firoozabadi Hospital in 2021. Clinical outcomes, including the length of hospital stay, the need for a ventilator, and mortality, were compared between patients who received either dexamethasone (DXM) or methylprednisolone (MP). Data were analyzed by SPSS V.20 software at P < 0.05 as statistical significance. Results: The mean ± SD ages of the patients in the DXM and MP groups were 58.82 ± 19.29 and 60.66 ± 14.17 years, respectively, without a statistically significant difference (P > 0.05). The mean duration of hospitalization was 8.14 ± 4.36 days in the DXM group and 6.80 ± 3.34 days in the MP group (P = 0.295). Also, 19 (33.3%) cases in the DXM group an, 19 (39.6%) in the MP group needed mechanical ventilation during hospitalization (P = 0.546). Finally, 30 (52.6%) patients in the DXM group and 27 (56.2%) in the MP group died. Conclusions: The findings indicated no significant difference in the mean duration of hospitalization, the need for a ventilator, and mortality in COVID-19 ICU patients treated with methylprednisolone or dexamethasone. There is a need to perform meta-analyses owing to conflicting results regarding the effects of different corticosteroids on the COVID-19 course.
- 11 September 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (2)
Open AccessEfficacy of Dexamethasone and Methylprednisolone in Hospitalization Outcomes of COVID-19 Patients: A Comparative Retrospective Study
Background: Control of the COVID-19 pandemic, its treatment, and prevention of mortality and morbidity have been the main focus of researchers over the past two years. Due to disagreement on the usefulness of different corticosteroids in the treatment of COVID-19, this work compared the efficacy of dexamethasone and methylprednisolone in the treatment outcomes of intensive critical care (ICU) patients. Methods: The present retrospective cohort study examined clinical records of 105 COVID-19 patients hospitalized in the ICUs of Firoozabadi Hospital in 2021. Clinical outcomes, including the length of hospital stay, the need for a ventilator, and mortality, were compared between patients who received either dexamethasone (DXM) or methylprednisolone (MP). Data were analyzed by SPSS V.20 software at P < 0.05 as statistical significance. Results: The mean ± SD ages of the patients in the DXM and MP groups were 58.82 ± 19.29 and 60.66 ± 14.17 years, respectively, without a statistically significant difference (P > 0.05). The mean duration of hospitalization was 8.14 ± 4.36 days in the DXM group and 6.80 ± 3.34 days in the MP group (P = 0.295). Also, 19 (33.3%) cases in the DXM group an, 19 (39.6%) in the MP group needed mechanical ventilation during hospitalization (P = 0.546). Finally, 30 (52.6%) patients in the DXM group and 27 (56.2%) in the MP group died. Conclusions: The findings indicated no significant difference in the mean duration of hospitalization, the need for a ventilator, and mortality in COVID-19 ICU patients treated with methylprednisolone or dexamethasone. There is a need to perform meta-analyses owing to conflicting results regarding the effects of different corticosteroids on the COVID-19 course.